If You Invested in In8Bio, Inc. (INAB)

IN8bio, Inc. (Nasdaq: INAB) is a clinical-stage biopharmaceutical company focused on the discovery and development of gamma-delta (γδ) T cell-based therapies. According to company disclosures, IN8bio develops γδ T cell product candidates for cancer and autoimmune diseases, targeting areas of significant unmet medical need. The company’s work centers on specialized γδ T cells, which are described as having the ability to differentiate between healthy and diseased tissue.

IN8bio’s pipeline is built around several named product candidates and platforms. The company identifies its lead program, INB-100, as a donor-derived, haplo-matched allogeneic γδ T cell therapy being evaluated in patients with leukemias, including acute myeloid leukemia, following hematopoietic stem cell transplantation. Clinical data presented from the INB-100 trial highlight durable, relapse-free survival in adult AML patients and long-term expansion and persistence of allogeneic γδ T cells through one year post-treatment.

In solid tumors, IN8bio is developing autologous γδ T cell therapies in combination with standard of care for glioblastoma (GBM). The company reports that INB-200, described as the first genetically modified γδ T cell therapy evaluated in GBM, and INB-400, a Phase 2 program in newly diagnosed GBM, use its DeltEx™ Drug-Resistant Immunotherapy (DRI) γδ T cells. These cells are delivered in the post-surgical setting alongside maintenance chemotherapy. Across Phase 1 INB-200 and Phase 2 INB-400 trials, IN8bio has disclosed data showing extended median progression-free survival compared with historical and contemporaneous standard-of-care Stupp protocol cohorts, with repeated dosing associated with prolonged progression-free survival and a favorable safety profile without dose-limiting toxicities, cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity (ICANS).

Beyond cell therapies, IN8bio is advancing γδ T cell engager (TCE) programs. The company describes INB-619 as a CD19-targeted, pan-γδ T cell engager designed to activate and expand multiple γδ T cell subsets (including Vδ1+ and Vδ2+). Preclinical data reported by IN8bio show that INB-619 can achieve complete depletion of B cells in systemic lupus erythematosus (SLE) donor models and lupus patient samples, with efficacy comparable to approved CD19 and CD20 engagers such as blinatumomab and mosunetuzumab, while demonstrating minimal secretion of inflammatory cytokines like IL-6. Company communications emphasize that INB-619’s targeted immune activation and cytokine-sparing design may support deep B cell depletion and immune modulation in autoimmune and oncology settings.

IN8bio also references an INB-600 γδ T cell engager platform, which it describes as a program advancing novel γδ T cell engagers for potential oncology and autoimmune indications. Across its programs, the company consistently highlights the distinct biology of γδ T cells, including potent cytotoxic activity with low or no cytokine release, and their ability to distinguish diseased from healthy tissues.

A key operational element disclosed by IN8bio is its proprietary γδ T cell manufacturing capability. The company has presented data from its DeltEx™ Allo manufacturing process used in the INB-100 trial, showing consistent reprogramming of donor T cells from αβ-TCR to γδ-TCR dominance, enrichment of Vγ9 clones, and high expression of genes associated with cancer killing, immune activation, and tumor-directed migration across multiple clinical batches. IN8bio reports that it maintains direct control over process development, clinical manufacturing and product characterization, and that its manufacturing has been automated to enable rapid and reproducible production of cryopreserved cell therapy doses.

IN8bio states that it is a clinical-stage company, meaning its candidates are in preclinical and early- to mid-stage clinical development rather than being approved commercial therapies. The company’s securities filings confirm that its common stock, with a par value of $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol INAB. An 8-K filing notes that Nasdaq confirmed the company’s regained compliance with the minimum bid price listing rule, indicating that IN8bio continues to meet that particular listing requirement.

According to multiple press releases, IN8bio is based in New York, New York. Its disclosures repeatedly describe a focus on oncology indications such as newly diagnosed glioblastoma and leukemias, as well as autoimmune diseases where B cell depletion and immune reset are important therapeutic goals. The company emphasizes its DeltEx™ platform, γδ T cell engagers, and manufacturing know-how as core elements supporting its development strategy.

Business focus and development stage

IN8bio characterizes itself as a biopharmaceutical company engaged in the development of γδ T cell product candidates rather than a diversified pharmaceutical business. Its public communications focus on investigational therapies in defined clinical trials and preclinical studies, including:

• INB-100 – donor-derived, allogeneic γδ T cells for leukemias in the post-transplant setting.
• INB-200 – autologous, genetically modified DeltEx DRI γδ T cells for newly diagnosed GBM in combination with standard-of-care therapy.
• INB-400 – a Phase 2 GBM program using DeltEx DRI γδ T cells across multiple centers.
• INB-619 – a CD19-targeted, pan-γδ T cell engager for B cell-driven autoimmune disease and oncology applications.
• INB-600 – a platform for novel γδ T cell engagers in oncology and autoimmune indications.

Across these programs, IN8bio’s disclosures emphasize clinical endpoints such as progression-free survival, overall survival, safety and tolerability, B cell depletion, γδ T cell expansion, and cytokine profiles, reflecting the types of outcomes that are central to oncology and immunology drug development.

Regulatory and public company context

As an SEC-reporting company, IN8bio files current reports on Form 8-K to describe material events, including clinical data presentations, financial results, and Nasdaq listing status. In these filings, the company reiterates that its common stock is listed on Nasdaq under the ticker INAB. The filings also incorporate press releases that summarize trial updates, preclinical findings, and financing activities, providing investors with additional context on the company’s progress and plans.

FAQs about IN8bio, Inc. (INAB)